KR101838326B1 - 헤테로아릴술폰아미드 유도체, 이의 제조방법 및 인간치료에서의 용도 - Google Patents

헤테로아릴술폰아미드 유도체, 이의 제조방법 및 인간치료에서의 용도 Download PDF

Info

Publication number
KR101838326B1
KR101838326B1 KR1020137015172A KR20137015172A KR101838326B1 KR 101838326 B1 KR101838326 B1 KR 101838326B1 KR 1020137015172 A KR1020137015172 A KR 1020137015172A KR 20137015172 A KR20137015172 A KR 20137015172A KR 101838326 B1 KR101838326 B1 KR 101838326B1
Authority
KR
South Korea
Prior art keywords
compound
phenyl
formula
pyridine
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137015172A
Other languages
English (en)
Korean (ko)
Other versions
KR20130119943A (ko
Inventor
엘리사베뜨 뒤퐁-파쎄레귀
이사벨 르 로이
끄리스또프 피그니에르
Original Assignee
피에르 파브르 메디카먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에르 파브르 메디카먼트 filed Critical 피에르 파브르 메디카먼트
Publication of KR20130119943A publication Critical patent/KR20130119943A/ko
Application granted granted Critical
Publication of KR101838326B1 publication Critical patent/KR101838326B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137015172A 2010-11-23 2011-11-23 헤테로아릴술폰아미드 유도체, 이의 제조방법 및 인간치료에서의 용도 Expired - Fee Related KR101838326B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1059634A FR2967674B1 (fr) 2010-11-23 2010-11-23 Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
FR1059634 2010-11-23
PCT/EP2011/070736 WO2012069503A1 (en) 2010-11-23 2011-11-23 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy

Publications (2)

Publication Number Publication Date
KR20130119943A KR20130119943A (ko) 2013-11-01
KR101838326B1 true KR101838326B1 (ko) 2018-03-13

Family

ID=44246390

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137015172A Expired - Fee Related KR101838326B1 (ko) 2010-11-23 2011-11-23 헤테로아릴술폰아미드 유도체, 이의 제조방법 및 인간치료에서의 용도

Country Status (19)

Country Link
US (2) US8846930B2 (cg-RX-API-DMAC7.html)
EP (1) EP2643318A1 (cg-RX-API-DMAC7.html)
JP (1) JP5837085B2 (cg-RX-API-DMAC7.html)
KR (1) KR101838326B1 (cg-RX-API-DMAC7.html)
CN (1) CN103209980B (cg-RX-API-DMAC7.html)
AR (1) AR083903A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011333772B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013012615A2 (cg-RX-API-DMAC7.html)
CA (1) CA2817531A1 (cg-RX-API-DMAC7.html)
FR (1) FR2967674B1 (cg-RX-API-DMAC7.html)
IL (1) IL226495A (cg-RX-API-DMAC7.html)
MA (1) MA34658B1 (cg-RX-API-DMAC7.html)
MX (1) MX352396B (cg-RX-API-DMAC7.html)
MY (1) MY168283A (cg-RX-API-DMAC7.html)
NZ (1) NZ610700A (cg-RX-API-DMAC7.html)
RU (1) RU2582995C2 (cg-RX-API-DMAC7.html)
TW (1) TWI576106B (cg-RX-API-DMAC7.html)
UA (1) UA109295C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012069503A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
EP2704720B1 (en) * 2011-05-03 2019-08-07 Agios Pharmaceuticals, Inc. Pyruvate kinase r activators for use in therapy
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015055447A1 (en) * 2013-10-17 2015-04-23 Basf Se Process for preparing substituted isatoic acid anhydride compounds and derivatives thereof
WO2015095111A1 (en) * 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Diazepane orexin receptor antagonists
CN104292179A (zh) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 一种2-氯苯并[d]恶唑-5-甲醛的制备方法
FR3029112A1 (fr) * 2014-12-02 2016-06-03 Pf Medicament Dispersion solide a base de derives d'heteroarylsulfonamides a usage pharmaceutique
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
EP3601273B1 (en) * 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN107556266B (zh) * 2017-09-12 2021-04-23 华南农业大学 一种2-巯基-4-取代-6-氟苯并噻唑及其制法、应用
US20200131156A1 (en) * 2018-10-30 2020-04-30 H. Lundbeck A/S ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
CN113200934B (zh) * 2021-05-18 2022-05-31 郑州大学 含苯并吗啉酮-联苯骨架化合物及其制备方法和应用
CN113912595B (zh) * 2021-10-12 2024-03-15 中国药科大学 一类含有噻唑或噻二唑结构的化合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130986A1 (en) 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2009055357A1 (en) 2007-10-25 2009-04-30 Boehringer Ingelheim International Gmbh Diazepane compounds which modulate the cb2 receptor
WO2009149508A1 (en) 2008-06-13 2009-12-17 Bionomics Limited Novel potassium channel blockers and uses thereof
WO2010111948A1 (zh) 2009-03-31 2010-10-07 中国药科大学 芳甲胺类化合物、其制备方法及其医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149700A (en) * 1990-05-30 1992-09-22 American Home Products Corporation Substituted arylsulfonamides and benzamides
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
PL1828154T3 (pl) * 2004-12-09 2009-10-30 Hoffmann La Roche Pochodne fenylopiperazynometanonu
CN101296914B (zh) * 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
WO2010130638A1 (en) * 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130986A1 (en) 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2009055357A1 (en) 2007-10-25 2009-04-30 Boehringer Ingelheim International Gmbh Diazepane compounds which modulate the cb2 receptor
WO2009149508A1 (en) 2008-06-13 2009-12-17 Bionomics Limited Novel potassium channel blockers and uses thereof
WO2010111948A1 (zh) 2009-03-31 2010-10-07 中国药科大学 芳甲胺类化合物、其制备方法及其医药用途

Also Published As

Publication number Publication date
NZ610700A (en) 2014-12-24
HK1187345A1 (en) 2014-04-04
IL226495A0 (en) 2013-07-31
BR112013012615A2 (pt) 2016-09-06
MX2013005734A (es) 2013-08-01
US8846930B2 (en) 2014-09-30
AR083903A1 (es) 2013-04-10
CA2817531A1 (en) 2012-05-31
FR2967674B1 (fr) 2012-12-14
UA109295C2 (uk) 2015-08-10
CN103209980B (zh) 2015-06-03
CN103209980A (zh) 2013-07-17
RU2582995C2 (ru) 2016-04-27
AU2011333772A1 (en) 2013-06-06
US20140357624A1 (en) 2014-12-04
RU2013126251A (ru) 2014-12-27
TW201225951A (en) 2012-07-01
US20130172326A1 (en) 2013-07-04
US9156834B2 (en) 2015-10-13
IL226495A (en) 2017-06-29
MA34658B1 (fr) 2013-11-02
AU2011333772B2 (en) 2016-08-18
EP2643318A1 (en) 2013-10-02
KR20130119943A (ko) 2013-11-01
MX352396B (es) 2017-11-22
FR2967674A1 (fr) 2012-05-25
JP5837085B2 (ja) 2015-12-24
WO2012069503A1 (en) 2012-05-31
JP2014502268A (ja) 2014-01-30
MY168283A (en) 2018-10-19
TWI576106B (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
RU2582995C2 (ru) Производные гетероарилсульфонамидов, их получение и применение для лечения человека
EP2528897B1 (en) Di-substituted pyridine derivatives as anticancers
CN102341385B (zh) 能够抑制前列腺素d合酶的哌嗪化合物
WO2011094890A1 (en) Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EP1783116B1 (en) 2-phenylpyridine derivative
EP3796975B1 (en) Sulfonylaminobenzamide derivatives
TW201443025A (zh) 化學化合物
ES2715394T3 (es) Nuevo antifúngico derivado de oxodihidropiridinacarbohidrazida
JP2013047223A (ja) 医薬
CN107001351B (zh) 可用于治疗特别是糖尿病的2-(1,2,4-三唑-3-基硫烷基)-n-1,3,4-噻二唑-2-基乙酰胺的衍生物
WO2006075955A1 (en) Pyrazolyl acylsulfonamide derivatives as endothelin converting enzyme inhibitors and useful in the treatment of chronic obstructive pulmonary disease
HK1187345B (en) Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
CN101010300A (zh) 2－苯基吡啶衍生物
CA3099051C (en) Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
OA16434A (en) Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy.
WO2022192162A1 (en) Novel heteroaromatic compounds exhibiting antifungal activity and their method of use
KR20130133229A (ko) 디아릴피리다지논 유도체, 이의 제조방법 및 인간치료에서의 용도
BR112020007177B1 (pt) Compostos derivados de fenilpiridina, composição farmacêutica compreendendo os mesmos e uso dos ditos compostos para prevenir ou tratar doenças autoimunes ou cânceres

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210308

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210308

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000